Company Announcement Net sales of DARZALEX® in the third quarter of 2021 totaled USD 1,580 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; Octob.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021 ugebrev.dk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ugebrev.dk Daily Mail and Mail on Sunday newspapers.
Genmab Announces that Janssen has Received European globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
Genmab A/SApril 20, 2021 GMT
Company Announcement
Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
Copenhagen, Denmark; April 20, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous formulation (sold under the tradename DARZALEX
FASPRO ® in the U.S.), as reported by Johnson & Johnson were USD 1,365 million in the first quarter of 2021. Net trade sales were USD 691 million in the U.S. and USD 674 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX and DARZALEX